Targeted protein degrader therapeutics - Roivant Sciences
Latest Information Update: 11 Jan 2021
At a glance
- Originator Roivant Sciences
- Class Antineoplastics; Neuroprotectants
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer; Neurological disorders
Most Recent Events
- 06 Dec 2020 Preclinical trials in Autoimmune disorders in Switzerland (unspecified route) before December 2020
- 06 Dec 2020 Preclinical trials in Cancer in Switzerland (unspecified route) before December 2020 (9310493
- 06 Dec 2020 Preclinical trials in Neurological disorders in Switzerland (unspecified route) before December 2020